Neupro (Rotigotine)

Rotigotine is a dopamine agonist used in the management of movement disorders.

• Parkinson's disease: Improves overall motor function and reduces rigidity, tremor, and bradykinesia in adults with idiopathic Parkinson's disease.
• Motor fluctuations in Parkinson's disease: Provides continuous dopaminergic stimulation to lessen OFF episodes and improve wearing‑off phenomena.
• Restless Legs Syndrome: Decreases the frequency and severity of uncomfortable leg sensations and urges to move in adults with moderate to severe RLS.

• Rotigotine is a non‑ergot dopamine agonist that binds to D1, D2 and D3 receptors in the central nervous system. By stimulating these receptors, it mimics the action of endogenous dopamine, enhancing dopaminergic neurotransmission in the basal ganglia and spinal pathways involved in motor control and sensory processing. Continuous transdermal delivery maintains stable plasma concentrations, reducing peaks and troughs associated with oral dosing.

Rotigotine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Skin irritation at the patch site: Redness, itching or rash where the patch is applied.
• Nausea: Mild to moderate feeling of stomach upset.
• Dizziness: Light‑headedness, especially when standing quickly.
• Somnolence: Increased sleepiness or fatigue during the day.
• Headache: Tension‑type or mild throbbing pain.
• Dry mouth: Reduced salivation causing thirst.
• Constipation: Decreased bowel movements.

Serious or Rare Side Effects

• Hallucinations: Visual or auditory disturbances that may affect perception.
• Impulse control disorders: Compulsive gambling, shopping or eating behaviors.
• Orthostatic hypotension: Significant drop in blood pressure upon standing, leading to faintness.
• Severe skin reactions: Bullous dermatitis or severe erythema requiring medical attention.
• Neuroleptic malignant syndrome: Rare but life‑threatening condition with fever, muscle rigidity and autonomic instability.

When prescribing rotigotine, clinicians should consider several precautionary measures to ensure safe use.

• Cardiovascular assessment: Evaluate for orthostatic hypotension or arrhythmias before initiating therapy.
• Psychiatric history: Monitor patients with a history of psychosis or impulse control disorders.
• Renal function: Adjust use cautiously in severe renal impairment.
• Hepatic impairment: Use with caution in moderate to severe liver disease.
• Pregnancy and lactation: Avoid use unless benefits outweigh potential risks, as safety data are limited.
• Store at room temperature: Keep patches below 25 °C in the original pouch, protected from moisture and direct sunlight.

Rotigotine can interact with other medicines, altering its effectiveness or increasing adverse effects.

Major Interactions (Avoid)

• MAO‑B inhibitors: Concomitant use may cause hypertensive crises or severe hypotension.
• Antipsychotics with strong dopamine antagonism: May reduce rotigotine’s efficacy and worsen motor symptoms.

Moderate Interactions (Monitor Closely)

• CYP1A2 inhibitors (e.g., fluvoxamine): Can increase rotigotine plasma levels.
• CYP3A4 inducers (e.g., carbamazepine): May reduce rotigotine exposure.
• Antihypertensive agents: Combined effect may exacerbate orthostatic hypotension.
• Other dopamine agonists: Additive risk of impulse control disorders.